A phase III, randomized, study of weekly Taxoprexin [DHA paclitaxel] plus carboplatin versus paclitaxel plus carboplatin as first line chemotherapy in patients with advanced non-small cell lung cancer

Trial Profile

A phase III, randomized, study of weekly Taxoprexin [DHA paclitaxel] plus carboplatin versus paclitaxel plus carboplatin as first line chemotherapy in patients with advanced non-small cell lung cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2017

At a glance

  • Drugs DHA-paclitaxel (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Luitpold Pharmaceuticals
  • Most Recent Events

    • 12 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top